Shopping Cart 0
Cart Subtotal
AED 0

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 38535

Details

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H2 2017

Summary

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Gastrointestinal, Cardiovascular, Central Nervous System and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Inflammation, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

The latest report Interleukin 1 Receptor Type 1-Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Overview

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Companies Involved in Therapeutics Development

Immune System Key Ltd

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Drug Profiles

anakinra-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL-1R1 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL1R1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-1510-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nerofe-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-130-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Dormant Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Discontinued Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Product Development Milestones

Featured News & Press Releases

Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor

Nov 16, 2017: First patient randomized in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still'sdisease

May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease

Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Nov 01, 2015: Immune System Key: Nerofe's Triple Action

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Apr 01, 2015: Immune System Key: Clinical Trial: Phase I Dose Escalation Completed Successfully With Exciting Results

Apr 23, 2014: First treatment for babies with ultra-rare spectrum of autoinflammatory diseases now available in UK

Dec 06, 2013: First treatment for infants with ultra-rare spectrum of autoinflammatory diseases licensed in UK

Sep 19, 2013: Swedish Orphan Biovitrum Receives CHMP Positive Opinion For Treatment Of Cryopyrin-Associated Periodic Syndrome

Jun 11, 2013: Sobi Gets FDA Approval To Manufacture Substance For Kineret With Partner Boehringer Ingelheim

Apr 18, 2013: Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease, Study Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Immune System Key Ltd, H2 2017

Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017

Pipeline by ProteoThera Inc, H2 2017

Pipeline by Swedish Orphan Biovitrum AB, H2 2017

Pipeline by XL-protein GmbH, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Immune System Key Ltd

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Company Profile

Company Profile Title

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Pipeline Review, H2 2017

Summary

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Gastrointestinal, Cardiovascular, Central Nervous System and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Inflammation, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

The latest report Interleukin 1 Receptor Type 1-Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Overview

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Companies Involved in Therapeutics Development

Immune System Key Ltd

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Drug Profiles

anakinra-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL-1R1 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL1R1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-1510-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nerofe-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-130-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Dormant Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Discontinued Products

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)-Product Development Milestones

Featured News & Press Releases

Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor

Nov 16, 2017: First patient randomized in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still'sdisease

May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease

Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Nov 01, 2015: Immune System Key: Nerofe's Triple Action

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Apr 01, 2015: Immune System Key: Clinical Trial: Phase I Dose Escalation Completed Successfully With Exciting Results

Apr 23, 2014: First treatment for babies with ultra-rare spectrum of autoinflammatory diseases now available in UK

Dec 06, 2013: First treatment for infants with ultra-rare spectrum of autoinflammatory diseases licensed in UK

Sep 19, 2013: Swedish Orphan Biovitrum Receives CHMP Positive Opinion For Treatment Of Cryopyrin-Associated Periodic Syndrome

Jun 11, 2013: Sobi Gets FDA Approval To Manufacture Substance For Kineret With Partner Boehringer Ingelheim

Apr 18, 2013: Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease, Study Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Immune System Key Ltd, H2 2017

Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017

Pipeline by ProteoThera Inc, H2 2017

Pipeline by Swedish Orphan Biovitrum AB, H2 2017

Pipeline by XL-protein GmbH, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Immune System Key Ltd

Paradigm Biopharmaceuticals Ltd

Paras Biopharmaceuticals Finland Oy

ProteoThera Inc

Swedish Orphan Biovitrum AB

XL-protein GmbH